# Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

> **NCT03897075** · PHASE3 · COMPLETED · sponsor: **Sun Pharmaceutical Industries Limited** · enrollment: 99 (actual)

## Conditions studied

- Chronic Plaque Psoriasis
- Moderate to Severe Nail Psoriasis

## Interventions

- **DRUG:** Tildrakizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03897075
- **Lead sponsor:** Sun Pharmaceutical Industries Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-13
- **Primary completion:** 2024-04-05
- **Final completion:** 2025-01-30
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03897075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03897075, "Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03897075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*